GH1 and major depressive disorder: Wexler et al. showed a significantly impaired quality of life in GH-deficient patients after treatment of acromegaly compared to GH-sufficient patients, as measured by the QoL-AGHDA, the Symptom Questionnaire Depression and SF36 questionnaires (19), while Vandeva et al. found that the absence of hypopituitarism independently predicted improvements in quality of life (10).